Clinical Trial Update: Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated symptom control with docetaxel versus no docetaxel in relapsed esophageal cancer or gastric/gastroesophageal junction adenocarcinoma. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Cambridge University Hospitals NHS Foundation Trust | Conditions: Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer | Phase 3 | Status: COMPLETED